Cerity Partners LLC Invests $654,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

Cerity Partners LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 60,933 shares of the company’s stock, valued at approximately $654,000.

A number of other hedge funds have also bought and sold shares of JANX. Nisa Investment Advisors LLC increased its position in Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after buying an additional 2,685 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Janux Therapeutics in the 4th quarter valued at about $57,000. SG Americas Securities LLC purchased a new stake in Janux Therapeutics during the fourth quarter valued at about $100,000. Old Well Partners LLC purchased a new position in Janux Therapeutics during the third quarter valued at approximately $104,000. Finally, Corton Capital Inc. bought a new stake in Janux Therapeutics during the 3rd quarter worth approximately $111,000. 75.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on JANX shares. Bank of America raised their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Cantor Fitzgerald started coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 target price on the stock. Wedbush reiterated an “outperform” rating and set a $53.00 price target on shares of Janux Therapeutics in a research report on Monday, March 11th. Finally, BTIG Research assumed coverage on shares of Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $61.33.

Janux Therapeutics Stock Up 1.8 %

NASDAQ JANX opened at $49.78 on Wednesday. The stock’s 50-day simple moving average is $36.84 and its two-hundred day simple moving average is $18.77. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $58.69. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -37.15 and a beta of 4.19.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. The company had revenue of $2.46 million for the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.